New Phase II study in gout patients shows Novartis ACZ885 prevented acute ... - PR-inside.com (press release)

New Phase II study in gout patients shows Novartis ACZ885 prevented acute ... PR-inside.com (press release) "Gout patients frequently experience painful flares with debilitating consequences on their quality of life because current treatment strategies are not ... EULAR: Novel Agent Eases Gout PainMedPage Today all 5 news articles »

Regeneron gout drug meets study goals - BusinessWeek

Regeneron gout drug meets study goals BusinessWeek A gout treatment candidate from Regeneron Pharmaceuticals met key goals in a late-stage clinical trial, the company said Wednesday. ... Regeneron gout drug works in one trial, fails otherReuters All About Gout: Arcalyst Meets Phase III Prophylaxis EndpointBioWorld Online Phase 3 trial of Arcalyst for prevention of gout flaresMonthly Prescribing Reference Wall Street Journal -PR Newswire (press release) -Motley Fool all 74 news articles »

Positive Clinical Findings Presented on XOMA 052 in Debilitating Eye Disease - MarketWatch (press release)

Positive Clinical Findings Presented on XOMA 052 in Debilitating Eye Disease MarketWatch (press release) Without immediate treatment, major exacerbations of Behcet's uveitis may lead to retinal detachment, vitreous hemorrhage, glaucoma and eventual blindness. ... and more »

Gout sufferers call pain 'miserable' - Dr. Cutler

Gout sufferers call pain 'miserable' Dr. Cutler Gout is a painful form of arthritis caused by a build-up of uric acid in the blood. Treatment often consists of medications and diet modifications to cut ... and more »